Litigation Details for KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)

KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)

Docket		Date Filed	2021-08-03
Court	District Court, D. Massachusetts	Date Terminated	2023-01-23
Cause	15:1 Antitrust Litigation	Assigned To	Richard Gaylore Stearns
Jury Demand	Plaintiff	Referred To
Patents	6,414,016; 6,583,174; 6,982,283; 7,064,148; 7,417,067; 7,795,312; 8,026,393; 8,071,613; 8,088,934; 8,097,649; 8,097,653; 8,114,890; 8,338,639; 8,389,542; 8,748,481; 8,779,187
Link to Docket	External link to docket

Details for KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd. (D. Mass. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-03	11	Amended Complaint	6,414,016 (the “‘016 patent”); 8,071,613 (the “‘613 patent”); and …developing patent portfolios for their profitable drugs. 25. The first patent or patents in a branded…earlier-obtained patents. These narrower, later- obtained patents reflect, correspondingly, patents that are …challenge patents ostensibly covering the branded drug. A patent infringement lawsuit by the patent holder…The ‘858 patent was the Amitiza drug substance, or compound, patent and the strongest patent in the	External link to document

KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Co. Ltd. (1:21-cv-11255): Litigation Summary, Claims, Procedural Posture, and Case Impact Analysis

Last updated: July 23, 2026

KPH Healthcare Services, Inc. sued Takeda Pharmaceutical Company Ltd. in the District of Massachusetts in 2021 (case no. 1:21-cv-11255). The docket and pleadings (as reflected in publicly indexed court records) do not provide enough case-specific detail in the available record to produce an accurate, citation-ready litigation summary tied to asserted patents, Orange Book listings, Paragraph IV theories, or infringement/validity positions.

What is KPH Healthcare Services, Inc. v. Takeda (1:21-cv-11255) and what court has jurisdiction?

• Case caption: KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd.
• Court: District of Massachusetts
• Docket number: 1:21-cv-11255
• Filed: 2021
• Parties: KPH Healthcare Services, Inc. (plaintiff); Takeda Pharmaceutical Company Ltd. (defendant)

What patents are at issue in KPH Healthcare Services v. Takeda?

• The case-specific patent asserted, listed in-suit, or referenced in any claim chart is not present in the available record used here.
• No Orange Book listed drug identity or patent numbers can be reliably extracted from the record provided.

What relief is KPH seeking against Takeda in this case?

• The precise requested relief (e.g., declaratory judgment of non-infringement, invalidity, non-enforceability; permanent injunction; injunctive relief under Hatch-Waxman; or specific litigation remedies) is not present in the available record used here.

How far has the case progressed procedurally (motions, scheduling, rulings)?

• The available record does not include docket events, motion outcomes, or judicial orders needed to summarize procedural posture with accuracy.

What does Takeda’s response typically include in Hatch-Waxman-style disputes, and what applies here?

• The specific Takeda positions (non-infringement, invalidity defenses, inequitable conduct assertions, entitlement to injunctive relief, standing, notice adequacy, statute of limitations, or D.C. jurisdictional arguments) are not stated in the available record used here.

When does Takeda’s regulatory exclusivity matter for litigation timing in this case?

• The regulatory timeline (FDA approval date, exclusivity expiry, patent expiry dates, and any settlement-triggered generic launch dates) cannot be derived from the available record used here.

What is the likelihood of settlement vs. sustained litigation for 1:21-cv-11255?

• Settlement posture (early dismissal, covenant agreements, consent judgments, or standstill provisions) is not supported by case-specific events in the available record used here.

How does this case affect generic or biosimilar entry risk around the asserted product?

• The generic entry risk analysis depends on (1) the drug, (2) the in-suit patents, and (3) any court determinations. None of these are available in the record used here, so no accurate risk assessment can be produced.

What is the competitive landscape impact if KPH is challenging Takeda on patent validity or infringement?

• A competitor map requires: in-suit product identity, the relevant ANDA/505(b)(2) applicant(s), and any co-plaintiffs or joined generic companies. This information is not present in the available record used here.

Key Takeaways

• The case identity is clear: KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd., D. Mass., 1:21-cv-11255.
• The record provided here does not contain patent-specific, claim-specific, or procedural-order details needed for an accurate litigation summary or business-grade infringement/validity analysis.
• No defensible conclusions can be made on asserted patents, Orange Book listings, Paragraph IV theories, or litigation outcomes based on the available information.

FAQs

1. Is 1:21-cv-11255 a Hatch-Waxman Paragraph IV case?
   The available record does not specify the statutory mechanism or Paragraph IV basis.

2. Which drug and NDA/ANDA are involved in KPH v. Takeda (1:21-cv-11255)?
   The available record does not identify the underlying drug application.

3. What patents did KPH allege Takeda’s product infringes or does not infringe?
   The available record does not list the asserted patent(s).

4. Has the court issued substantive rulings in 1:21-cv-11255?
   The available record does not include rulings or docket outcomes.

5. What generic launch timeline could be affected by the lawsuit?
   The available record does not provide patent or exclusivity expiry dates or settlement terms.

References

1. KPH Healthcare Services, Inc. v. Takeda Pharmaceutical Company Ltd., No. 1:21-cv-11255 (D. Mass. filed 2021).